The Asia Pacific Huntington's Disease Treatment Market is projected to witness market growth of 9.7% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Huntington's Disease Treatment Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $55.60 millions by 2031. The Japan market is registering a CAGR of 9% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 10.4% during (2024 - 2031).
Information on HD, its signs and symptoms, accessible treatments, and support services gives patients and carers the power to take an active role in their care and make educated decisions. HD can affect swallowing and speech abilities. Nutritional counseling and speech therapy help manage these challenges and maintain overall health.
Emerging neuroprotective strategies aim to preserve neuronal function, protect against neurodegeneration, and potentially delay disease onset or progression. Therapies targeting oxidative stress, mitochondrial function, and other neuroprotective mechanisms aim to enhance neuronal resilience and slow disease progression. Experimental approaches using stem cells to replace damaged neurons and promote neural regeneration are being explored for their potential to restore brain function in HD patients.
As the hospital sector expands in India, there is greater potential for establishing specialized neurology departments and clinics equipped to diagnose and manage complex neurological conditions like Huntington’s disease. The hospital sector in India, which makes up 80% of the country's healthcare business overall, is seeing strong investment demand from domestic and foreign investors, according to the National Investment Promotion and Facilitation Agency of India. The healthcare industry was expected to rise to $132 billion by 2023. In addition, Australia’s high prevalence of HD encourages focused genetic research to understand the disease’s underlying mechanisms and identify potential therapeutic targets. According to the Australian Government, the prevalence rate of Huntington’s disease was estimated at 8.4 per 100,000 people (about 2,160 people). About 830 people diagnosed with Huntington’s disease received a National Disability Insurance Scheme (NDIS) package on 31 December 2019. Hence, the rising hospital sector and the prevalence of HD are driving the market's growth.
The China market dominated the Asia Pacific Huntington's Disease Treatment Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $55.60 millions by 2031. The Japan market is registering a CAGR of 9% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 10.4% during (2024 - 2031).
Information on HD, its signs and symptoms, accessible treatments, and support services gives patients and carers the power to take an active role in their care and make educated decisions. HD can affect swallowing and speech abilities. Nutritional counseling and speech therapy help manage these challenges and maintain overall health.
Emerging neuroprotective strategies aim to preserve neuronal function, protect against neurodegeneration, and potentially delay disease onset or progression. Therapies targeting oxidative stress, mitochondrial function, and other neuroprotective mechanisms aim to enhance neuronal resilience and slow disease progression. Experimental approaches using stem cells to replace damaged neurons and promote neural regeneration are being explored for their potential to restore brain function in HD patients.
As the hospital sector expands in India, there is greater potential for establishing specialized neurology departments and clinics equipped to diagnose and manage complex neurological conditions like Huntington’s disease. The hospital sector in India, which makes up 80% of the country's healthcare business overall, is seeing strong investment demand from domestic and foreign investors, according to the National Investment Promotion and Facilitation Agency of India. The healthcare industry was expected to rise to $132 billion by 2023. In addition, Australia’s high prevalence of HD encourages focused genetic research to understand the disease’s underlying mechanisms and identify potential therapeutic targets. According to the Australian Government, the prevalence rate of Huntington’s disease was estimated at 8.4 per 100,000 people (about 2,160 people). About 830 people diagnosed with Huntington’s disease received a National Disability Insurance Scheme (NDIS) package on 31 December 2019. Hence, the rising hospital sector and the prevalence of HD are driving the market's growth.
List of Key Companies Profiled
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Dr.Reddy’s Laboratories Ltd.
- Neurocrine Biosciences Inc.
- Pfizer, Inc.
- F.Hoffmann-La Roche Ltd.
Market Report Segmentation
By Drug Type- Approved Drugs
- Tetrabenazine
- Deutetrabenazine
- Offlabel Drugs
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Pharmacies
- Below 50 years
- Above 50 years
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Huntington’s Disease Treatment Market by Drug Type
Chapter 5. Asia Pacific Huntington’s Disease Treatment Market by Distribution Channel
Chapter 6. Asia Pacific Huntington’s Disease Treatment Market by Age
Chapter 7. Asia Pacific Huntington’s Disease Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Neurocrine Biosciences Inc.
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd.
Methodology
LOADING...
